ClinicalTrials.gg
RecruitingNCT06872905Updated Nov 4, 2026

Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used in Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) to Treat Aortoiliac Occlusive Disease

An observational study in Aortoiliac Occlusive Disease, sponsored by W.L.Gore & Associates. Recruiting at 27 sites in 5 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by W.L.Gore & Associates · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 5 months later.
Updated Nov 4, 2026Site recruiting status changed2 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
158
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The study will assess the safety and effectiveness of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis ("VBX Device" or also referred to as "VBX Stent Graft") in a post approval setting and evaluate the quality of the use in covered endovascular reconstruction of the aortic bifurcation (CERAB) to treat Aortoiliac Occlusive Disease (AIOD).

Read the detailed description

A minimum of 158 adult subjects will be enrolled at up to a minimum of 20 sites in the U.S. and Europe. Data will be collected retrospectively and found within existing site files at Baseline, Treatment, Discharge, Pre-12-Month Follow-up, 12-Month Follow-Up, Subsequent Follow-Up Visits.

02

Conditions studied

  • Aortoiliac Occlusive Disease
03

In context

Lead sponsor

W.L.Gore & Associates is the lead sponsor of 96 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

As described in the background section, patients with aortoiliac occlusive disease are treated with various surgical and endovascular therapies to improve arterial blood flow to the lower extremity. This study will retrospectively evaluate a population of patients that have had covered endovascular reconstruction of the aortic bifurcation (CERAB) with GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis.

The study has been designed with standard eligibility criteria to evaluate the safety and effectiveness of the VBX Device when used in a CERAB for an aortoiliac occlusive disease patient population.

Considering the nature of aortoiliac occlusive disease, elderly patients (≥ 65 years old) can represent a significant number of patients enrolled in this study. This population can include patients with cognitive disorder or severe dementia.

According to EU regulation, elderly patients are considered vulnerable population. However, considering the retrospective nature of the study design, t

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient treated with covered endovascular reconstruction of the aortic bifurcation (CERAB) procedure for aortoiliac occlusive disease (AIOD).
  2. Patient was implanted with the VBX Device in the aortic position during a CERAB procedure.
  3. Patient was treated with the CERAB procedure a minimum of 1 year before enrollment date.
  4. Age ≥18 years at the time of CERAB procedure.
  5. Obtain patient or waiver according to local Institutional Review Board (IRB)/Ethics Committee (EC) -

Exclusion criteria

Exclusion Criteria:

  1. Patient with prior stenting in the aortic or common iliac artery at the time of CERAB procedure.
  2. Patient treated with concomitant chimney procedure at time of CERAB procedure (e.g., inferior mesenteric artery, renal artery).
  3. Participation in another drug or device study at the time of the CERAB procedure date that can confound the study endpoints.

    -

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
158 participants (estimated)
Patient registry
No

Groups and cohorts

  • GORE VIABAHN® VBX Balloon Expandable Endoprosthesis

    Patient was implanted with the VBX Device in the aortic and common iliac positions during the CERAB procedure.

    Device: GORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX)

Interventions

  • DeviceGORE VIABAHN® VBX Balloon Expandable Endoprosthesis (VBX)

    Treatment of Target Lesions with the VBX Device in the aortic and common iliac positions during the CERAB procedure.

06

What researchers measure

Primary outcomes

  1. Primary Effectiveness Endpoint: 1-Year Primary patency (hypothesis testing)

    Proportion of patients maintaining primary patency at 1 Year

    Time frame: 1-Year

  2. Primary Safety Endpoint: 30-day Morbidity (hypothesis testing)

    Proportion of patients experiencing any major adverse cardiovascular event (i.e. myocardial infarction, cerebrovascular accident) or event requiring reintervention.

    Time frame: 30-Day

Secondary outcomes

  1. Technical Success

    Proportion of patients with technical success

    Time frame: At index procedure

  2. Mortality

    Proportion of patients with all cause death

    Time frame: 30-Day

  3. Device Integrity

    Proportion of patients achieving Primary Patency

    Time frame: 1 year

  4. Primary assisted patency

    Proportion of patients achieving Primary Assisted patency

    Time frame: 1 year

  5. Secondary patency

    Proportion of patients achieving Secondary Patency

    Time frame: 1 year

  6. Freedom from Target Lesion Revascularization

    Proportion of patients achieving freedom from Target Lesion Revascularization

    Time frame: 1 year

  7. Survival

    Proportion of patients survival

    Time frame: 1 Year

  8. Freedom from Clinically-Driven Target Lesion Revascularization

    Proportion of patients achieving freedom from Clinically-Driven Target Revascularization

    Time frame: 1 year

07

Study locations

25 of 27 sites recruiting
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
    Recruiting
  • University of California
    Fresno, California 93721, United States
    Recruiting
    • Jessica Gallegos · Contact
    • Leigh Ann O'Banion, MD · Principal investigator
  • University of South Florida
    Tampa, Florida 33606, United States
    Recruiting
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
    Recruiting
    • Samantha Knight · Contact
    • Fahad Shuja, MBBS · Principal investigator
  • Cooper University Hospital
    Camden, New Jersey 08103, United States
    Recruiting
    • Jonelle O'Shea · Contact
    • Laurel Hastings, MD · Principal investigator
  • Rutgers
    New Brunswick, New Jersey 08901, United States
    Recruiting
    • Marie Macor · Contact
    • William Beckerman, MD · Principal investigator
  • Research Foundation SUNY Buffalo
    Buffalo, New York 14203, United States
    Recruiting
    • Dawn Holler · Contact
    • Linda Harris, MD · Principal investigator
  • Mount Sinai Medical Center
    New York, New York 10029, United States
    Recruiting
    • Bridget Coyle · Contact
    • Ajit Rao, MD · Principal investigator
  • Research Foundation at SUNY Syracuse
    Syracuse, New York 13210, United States
    Recruiting
    • Maria Walker · Contact
    • Palma Shaw, MD · Principal investigator
    • Fawaz Araim, MD · Sub investigator
  • Atrium Health Sanger Heart & Vascular Institute
    Charlotte, North Carolina 28203, United States
    Recruiting
    • Houston Chapman · Contact
    • Hector Crespo-Soto, MD · Principal investigator
  • Ohio State University Medical Center
    Columbus, Ohio 43210, United States
    Recruiting
    • Subhashish Das · Contact
    • Kyongjune Lee, MD · Principal investigator
  • Integris Health Baptist Medical Center
    Oklahoma City, Oklahoma 73112, United States
    Recruiting
  • Geisinger Medical Center
    Danville, Pennsylvania 17822, United States
    Recruiting
    • Rebecca Mack · Contact
    • Evan Ryer, MD · Principal investigator
  • University Of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Carolina Reyes · Contact
    • Grace WANG, MD · Principal investigator
  • Sanford Clinical Vascular Associates
    Sioux Falls, South Dakota 57105, United States
    Recruiting
    • Karla Reily · Contact
    • Anand Dayama, MD · Principal investigator
  • Wellmont Holston Valley Medical Center
    Kingsport, Tennessee 37760, United States
    Recruiting
    • Ashley Bowen · Contact
    • Ryan Cronin, MD · Principal investigator
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Completed

    Not enrolling at this site — choose another above.

  • The University of Texas Austin
    Austin, Texas 78712, United States
    Recruiting
    • Andrea Stapper · Contact
    • Meryl Logan, MD · Principal investigator
  • University of Virginia
    Charlottesville, Virginia 22908, United States
    Recruiting
    • Robin Kelly · Contact
    • Behzad Farivar, MD · Principal investigator
  • Carilion Clinic
    Roanoke, Virginia 24016, United States
    Recruiting
    • Yili Zhong · Contact
    • Esmaeel Dadashzadeh, MD · Principal investigator
  • Marshfield Medical Center - Marshfield
    Marshfield, Wisconsin 54449, United States
    Recruiting
    • Angela Varsho · Contact
    • Shameem Kunhammed, MD · Principal investigator
  • Azienda Ospedaliero-Universitaria di Padova
    Padova, 35131, Italy
    Not yet recruiting
  • Ospedale di Circolo e Fondazione Macchi
    Varese, 21100, Italy
    Recruiting
    • Gabriele Piffaretti · Contact
    • Gabriel Piffaretti, MD · Principal investigator
  • Amsterdam UMC Research BV
    Amsterdam, 1105, Netherlands
    Recruiting
    • Rutger Lely · Contact
    • Rutger Lely, MD · Principal investigator
  • Franciscus
    Rotterdam, 3045 PM, Netherlands
    Recruiting
    • Jerome van Brussel · Contact
    • Jerome van Brussel, MD · Principal investigator
  • Hospital General Universitario de Alicante
    Alicante, 03010, Spain
    Recruiting
    • Elisabeth Cruces Fuentes · Contact
    • Elisabeth Cruces Fuentes, MD · Principal investigator
  • Greater Glasgow Health Board
    Glasgow, G12 OXH, United Kingdom
    Recruiting
    • Martin Hennessy · Contact
    • Martin Hennessy, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Aug 2027, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2025
First posted
Mar 12, 2025
StartActual
May 30, 2025
Primary completionEst.
Aug 16, 2027
CompletionEst.
Aug 16, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed. Vanderbilt University Medical Center is now Completed
Show 2 added (2 United States)
  • University of Alabama at Birmingham · Birmingham, United States
  • Integris Health Baptist Medical Center · Oklahoma City, United States
Show 1 removed
  • Marshfield Hospital · Marshfield, United States
Nov 4, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Vanderbilt University Medical Center · Nashville, United StatesContact removed (no phone or email listed)Contact removed (no phone or email listed)
  • Azienda Ospedaliero-Universitaria di Padova · Padova, ItalyContact added m•••@unipd.it · •••8736
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    2 sites added, 1 site removed. Vanderbilt University Medical Center is now Completed
    Show 2 added (2 United States)
    • University of Alabama at Birmingham · Birmingham, United States
    • Integris Health Baptist Medical Center · Oklahoma City, United States
    Show 1 removed
    • Marshfield Hospital · Marshfield, United States
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Vanderbilt University Medical Center · Nashville, United StatesContact removed (no phone or email listed)Contact removed (no phone or email listed)
    • Azienda Ospedaliero-Universitaria di Padova · Padova, ItalyContact added m•••@unipd.it · •••8736
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06872905
Responsible party
Sponsor
First posted
Mar 12, 2025
Start date
May 30, 2025
Primary completion
Aug 16, 2027 (estimated)
Completion
Aug 16, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Jennifer Camoriano, BS
Contact
jcamoria@wlgore.com
14805365820
Chris Timberlake, BS
Contact
ctimberl@wlgore.com
1-928-707-4974
Leigh Ann O'Banion, M.D.
principal investigator · University of California, San Francisco
Michele Antonello, M.D.
principal investigator · Azienda Ospedaliero-Universitaria di Padova

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion